Ranbaxy Fights To Convince Sales Staff No Changes With Daiichi Buy
This article was originally published in PharmAsia News
Executive Summary
Even as Japan's Daiichi Sankyo's bid to buy India's Ranbaxy Laboratories neared completion, sales personnel, some of them with the company for more than two decades, face a new way in doing business. Ranbaxy's sales force numbers about 2,000, but as part of Daiichi it now is representing the world's 15th largest drug maker. The head of that force, Vivek Sawant, says physicians at first had a hard time believing the Ranbaxy operation would remain unchanged by the merger. Some doctors, and the medical representatives who deal with them, had problems with the idea of losing a local company to a foreign owner, but thanks to a strong effort, Ranbaxy believes it has convinced physicians its products and service would remain unchanged. (Click here for more